Novavax Inc. (Nasdaq: NVAX) reported positive results from a Phase 2 clinical trial of its RSV F-protein recombinant nano particle vaccine candidate but the stock price tumbled $1.74 to close at $6.41.
Positive trial results for Novavax
September 29, 2015 at 19:35 PM EDT
